신체질환을 앓고 있는 정신과환자에서의 정신약물의 사용

키워드

참고문헌 (67)

1. Ray WA, "Antipsychotics and the Risk of Sudden Cardiac Death", 58, pp.1161~1167 (2001)
2. Taylor D, "The Maudsley Pres-cribing Guidelines" (2007), ondon and New York: In-forma Healthcare
3. Haddad PM, "Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death", 62, pp.1649~1671 (2002)
4. Taylor DM, "Antipsychotics and QT prolongation", 107, pp.85~95 (2003)
5. Hod SD, "Antipsychotics", 6, pp.295~300 (2007)
6. Kerwina R, "Pharmacological treatment of schizophrenia", 4, pp.36~39 (2005)
7. Lerner V, "Combina-tion of atypical antipsychotic medication in the ma-nagement of treatment-resistant schizophrenia and schizoafective disorder", 28, pp.89~98 (2004)
8. Kang UG, "Electrocardiographic Abnormalities in Patients Treated With Clozapine", 61, pp.441~446 (2000)
9. Kilian JG, "Myo-carditis and cardiomyopathy associated with clozapine", 354, pp.1841~1845 (1999)
10. Marder SR, "Efficacy and Safety of Paliperi-done Extended-Release Tablets: Results of a 6-Wek, Randomized, Placebo-Controlled Study", 62, pp.1363~1370 (2007)
11. Lin WW, "Clinical efficacy, body weight ch-ange and cardiac safety of zotepine in schizophrenic patients", 16, pp.415~416 (2006)
12. Lesperance F, "Depre-ssion following myocardial infarction Impact on 6-month survival"
13. Ziegelstein RC, "Patients With Depre-ssion Are Less Likely to Follow Recommendations to Reduce Cardiac Risk During Recovery From a Myo-cardial Infarction", 160, pp.1818~1823 (2000)
14. "Thase ME. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients", 59, pp.502~508 (1998)
15. Letsas K, "QT interval prolongation ass-ociated with venlafaxine administration", 109, pp.116~117 (2006)
16. Mallinckrodt CH, "Duloxetine for the treatment of major depresive disorder: A closer look at efficacy and safety data across the approved dose range", 40, pp.337~348 (2006)
17. Fisch C, "Effect of fluoxetine on the electrocardiogram", pp.42~4
18. Roose SP Glassman AH, "Cardiovascular effects of fluo-xetine in depressed patients with heart disease", 155, pp.660~665 (1998)
19. Rasmussen SL, "Cardiac safety of citalopram: Prospective trials and retrospective analy-ses", 19, pp.407~415 (1999)
20. Hippisley-Cox J, "Antidepressants as risk factor for ischaemic heart disease: case-control study in pri-mary care", 323, pp.666~669 (2001)
21. Harrigan RA, "ECG abnormalities in tricyclic antidepressant ingestion", 17, pp.387~393 (1999)
22. Roose SP, "Considerations for the use of antidepres-sants in patients with cardiovascular disease", 140, pp.S84~S88 (2000)
23. Montgomery SA, "Safety of mirtazapine: a review", 10, pp.37~45 (1995)
24. Hilton S, "Moclobemide safety: Mo-nitoring a newly developed product in the 1990s", 15, pp.76~83 (1995)
25. Dosterta P, "eview of the pharmacokinetics and metabolism of reboxetine, a se-lective noradrenaline reuptake inhibitor", 7, pp.23~35 (1997)
26. Ahrens B, "Excess cardiovascular and sui-cide mortality of affective disorders may be reduced by lithium prophylaxis", 33, pp.67~75 (1995)
27. Paragas MG, "Lithium adverse reactions in psychiatric patients", pp.65~9
28. Stefan H, "Novel anticonvulsant drugs", 113, pp.165~183 (2007)
29. Fontaine R, "Double-blind comparison of buspirone 10 mg bid versus buspirone 5 mg tid in generalized anxiety disorder", pp.254~61
30. Montplaisir J, "Zopiclone and zaleplon vs benzodia-zepines in the treatment of insomnia: Canadian con-sensus statement", 18, pp.29~38 (2003)
31. Mujica R, "Sinus bradycardia related to the use of benztropine mesylate", voi(v h)
32. Guthrie SK, "Central and peripheral effects of trihexyphenidyl and biperi-den", 43, pp.43~ (1998)
33. Rogers SL, "Long-term efficacy and sa-fety of donepezil in the treatment of Alzheimers dise-ase An interim analysis of the results of a US multi-centre open label extension study", 8, pp.67~75 (1998)
34. Kavirajan H, "Efficacy and adverse effe-cts of cholinesterase inhibitors and memantine in vas-cular dementia a meta-analysis of randomised con-trolled trials", 6, pp.782~792 (2007)
35. Williams BR, "A review of riva-stigmine: A reversible cholinesterase inhibitor", 25, pp.1634~1653 (2003)
36. Mason BJ, "Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits asesment", 13, pp.469~475 (2003)
37. Kiefer F, "New achievements and pharmaco-therapeutic approaches in the treatment of alcohol de-pendence", 526, pp.163~171 (2005)
38. Mitler MM, "Long-term efficacy and safety of modafinil for the treatment of excesive daytime sleep-iness associated with narcolepsy", 1, pp.231~243 (2000)
39. , 2003, ~, pp.Princeton: Bristol-Meyers Squibb
40. Hummer M, "Hepatotoxicity of cloza-pine", 18, pp.126~127 (1996)
41. Thyrum PT, "Single-dose pharma-cokinetics of quetiapine in subjects with renal or hepatic impairment", 24, pp.521~533 (2000)
42. Vermeir M, "Absorption, metabolism and excretion of a single oral dose of 14Cpaliperidone 1 mg in healthy subjects", 15, pp.648~ (2005)
43. Stimmel GL, "Ziprasidone: An Atypical Antipsychotic Drug for the Treatment of Sch-izophrenia", 24, pp.21~37 (2002)
44. Nash J, "Antidepressants", 6, pp.289~294 (2007)
45. Vaswani M, "Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review", 27, pp.85~102 (2003)
46. Settle EC, "Safety Profile of Sustained-Release Bupropion in Depression: Results of Three Clinical Trials", 2, pp.454~463 (1999)
47. Fawcett J, "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression", 51, pp.267~285 (1998)
48. Dostert P, "Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor", 7, pp.23~S35 (1997)
49. Shire US Inc, "Equetro Prescribing Information" (2004), Penn-sylvania: Shire US Inc
50. Hirschfeld RMA, "Practice Guideline for the Treatment of Patients With Bipolar Disorder(Revision)", 1, pp.64~110 (2003)
51. Bryant III A, "Valproic acid hepatic fata-lities", 46, pp.465~469 (1996)
52. Morris GM, "Gabapentin", 40, pp.63~70
53. Matsuo F, "Lamotrigine", 40, pp.30~36 (1999)
54. Schachter SC, "Tiagabine", 40, pp.17~22 (1999)
55. Glauser TA, "Topiramate", 40, pp.71~80 (1999)
56. French JA, "Vigabatrin", 40, pp.11~16 (1999)
57. Bailey L, "Clinical pharmacokinetics of benzodiazepines", pp.804~11
58. Gammans RE, "Metabolism and disposition of buspirone", pp.41~51
59. Wagner J, "Non-benzodiazepines for the treatment of insomnia", 4, pp.551~581 (2000)
60. Elias TJ, "Clozapine-induced acute interstitial nephritis", 354, pp.1180~1181 (1999)
61. Snoeck E, "Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man", 122, pp.223~229 (1995)
62. Aweeka F, "The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function", 7, pp.214~215 (1997)
63. Gutierrez MA, "Venlafaxine: A 2003 Update", 25, pp.2138~2154 (2003)
64. , 2004, ~, pp.Indianapolis: Eli Lilly and Company
65. Hiemke C, "Pharmacokinetics of selective serotonin reuptake inhibitors", 85, pp.11~28 (2000)
66. Tiller JWG, "Clinical overview on moclobemide", pp.703~12
67. Gitlin M, "Lithium and the kidney, an updated review", 20, pp.231~243 (1999)

관련 논문AI추천